Poultry Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application (Broiler, Layer, Breeder), By Product (Attenuated Live Vaccines, Inactivated Vaccines, Subunit Vaccines, DNA Vaccines, Recombinant Vaccines), By Disease Type (Infectious Bronchitis, Infectious Bursal Diseases, Infectious Laryngotracheitis, Egg Drop Syndrome, Adenovirus, Duck Viral Enteritis, Inclusion Body Hepatitis, Salmonella, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 2.13 Billion
CAGR (2026-2031)	6.91%
Fastest Growing Segment	Broiler
Largest Market	North America
Market Size (2031)	USD 3.18 Billion

Market Overview

The Global Poultry Vaccines Market is projected to grow from USD 2.13 Billion in 2025 to USD 3.18 Billion by 2031 at a 6.91% CAGR. Poultry vaccines are biological preparations containing antigens administered to domesticated birds, such as broilers and layers, to stimulate immunity against infectious diseases. The market is primarily propelled by the rising global demand for affordable animal protein and the critical need to secure food supplies against outbreaks of zoonotic viruses like Avian Influenza. Additionally, the industry is pivoting from antibiotic reliance toward preventative prophylaxis due to stringent regulatory standards regarding antimicrobial resistance. According to the Brazilian Association of Animal Protein, in 2025, chicken production was projected to expand by 2.7%, demonstrating the continued scaling of livestock operations that necessitates rigorous vaccination schedules to maintain flock health.

A significant challenge constraining market growth is the logistical complexity and high cost of maintaining the cold chain infrastructure required for temperature-sensitive biologics. Inadequate refrigeration capabilities in developing regions frequently compromise vaccine efficacy and limit accessibility for small-scale poultry farmers, thereby impeding broader market penetration.

Key Market Drivers

The surge in global consumption of poultry meat and eggs serves as a primary engine for market expansion, necessitating higher stocking densities and optimized flock management to meet output targets. As producers intensify operations to satisfy this nutritional demand, the risk of disease transmission increases, making comprehensive immunization protocols essential for maintaining productivity and food security. This scaling of operations is evident in production forecasts. According to the USDA Foreign Agricultural Service, October 2024, in the 'Livestock and Poultry: World Markets and Trade' report, global chicken meat production is forecast to rise 2 percent to a record 105.3 million tons in 2025. This volume growth directly correlates with an increased requirement for prophylactic biologicals to safeguard these expanding commercial assets and minimize mortality rates in high-density farming environments.

Simultaneously, the escalating prevalence of infectious and zoonotic poultry diseases is compelling the industry to adopt advanced vaccination strategies. Outbreaks of pathogens such as Highly Pathogenic Avian Influenza (HPAI) cause severe economic losses and trade disruptions, prompting governments and integrators to prioritize preventative inoculation over reactive culling measures. For instance, according to the French Ministry of Agriculture and Food Sovereignty, October 2024, in the 'Launch of the Second Vaccination Campaign' press release, the state procured 67 million doses of vaccines to immunize commercial duck flocks for the 2024-2025 season. Furthermore, international trade relies heavily on disease-free certifications enabled by robust health programs. According to the USDA Foreign Agricultural Service, in 2024, global chicken meat exports were projected to reach 13.8 million tons for the upcoming year, underscoring the vital role of vaccination in sustaining the cross-border flow of poultry products.

Download Free Sample Report

Key Market Challenges

The logistical complexity and high cost of maintaining cold chain infrastructure constitute a severe impediment to the Global Poultry Vaccines Market. Most avian vaccines are temperature-sensitive biologics that rapidly degrade if exposed to heat, necessitating uninterrupted refrigeration from the point of manufacturing to farm-level administration. In many developing nations where the poultry sector is expanding, the lack of reliable electricity and specialized storage equipment frequently compromises vaccine stability. This logistical fragility erodes farmer confidence in immunization programs, as spoiled vaccines fail to protect flocks, leading to wasted expenditure and continued disease susceptibility. Consequently, market expansion is stifled in these high-potential regions because the necessary distribution network is often too costly or technically difficult to sustain for small-scale operators.

This infrastructural bottleneck creates a significant disconnect between the growing volume of livestock requiring immunization and the industry's ability to deliver effective products. According to the Food and Agriculture Organization, in 2025, global poultry meat production was projected to exceed 152 million metric tons, representing a massive target population that remains partially inaccessible to vaccine suppliers due to these supply chain deficits. Without a robust cold chain to ensure product efficacy across this expanding production base, manufacturers cannot fully capitalize on the global demand, effectively capping market revenue growth despite the intensifying prevalence of infectious threats.

Key Market Trends

Innovations in vaccine stability, particularly the emergence of thermostable and freeze-dried formulations, are transforming the market by mitigating the logistical risks associated with temperature-sensitive biologics. Manufacturers are aggressively expanding infrastructure to produce these advanced large-molecule formulations, which ensure product potency in regions with unreliable cold chains. This strategic pivot towards enhanced stability is exemplified by significant industrial investments to support complex biologic production. According to Merck Animal Health, May 2025, in the 'Merck Animal Health Announces $895 Million Investment in De Soto, Kansas' press release, the company committed $895 million to upgrade its manufacturing facilities, specifically focusing on expanding filling and freeze dryer capacity to support the production of large molecule vaccines and biologics.

Simultaneously, there is a surge in demand for multivalent combination vaccines, which allow producers to immunize flocks against concurrent threats like Newcastle and Gumboro diseases in a single administration. This shift is driven by the operational imperative to minimize bird handling stress and reduce labor costs while maximizing flock coverage efficiency. The commercial impact of this preference for comprehensive disease management solutions is evident in the financial performance of key industry players. According to Phibro Animal Health, February 2025, in the 'Phibro Animal Health Corporation Reports Second Quarter Results' report, the vaccine segment recorded a 12% increase in net sales, a growth trajectory attributed primarily to the rising adoption of poultry products in Latin America and other international regions.

Segmental Insights

The broiler segment represents the fastest-growing category within the global poultry vaccines market, primarily driven by the escalating worldwide demand for affordable animal protein. Producers are increasingly prioritizing immunization to mitigate economic losses from infectious outbreaks such as avian influenza and Newcastle disease. Furthermore, stringent regulations regarding antibiotic usage have compelled the industry to adopt vaccines as the primary method for disease prevention and herd health management. This shift is aligned with disease control standards advocated by the World Organisation for Animal Health to ensure food security and sustainable production practices.

Regional Insights

North America holds the leading position in the global poultry vaccines market due to high consumption rates of poultry products and strict regulatory standards regarding animal health. The dominance of the region is supported by the United States Department of Agriculture, which enforces rigorous protocols to control disease outbreaks and ensure food safety. Furthermore, the presence of major animal healthcare companies facilitates the widespread adoption of immunization programs across the sector. This systematic approach to disease prevention and established infrastructure drives the continuous expansion of the market in this region.

Recent Developments

• In February 2025, Zoetis announced that it had received a conditional license from the U.S. Department of Agriculture for a new avian influenza vaccine specifically labeled for use in chickens. The license covers a killed virus vaccine targeting the H5N2 subtype, which was developed to help the poultry industry manage the severe risks associated with highly pathogenic avian influenza. This regulatory milestone allowed the company to provide a critical, science-based tool for poultry producers facing ongoing disease challenges. The approval was granted based on data demonstrating the product's safety and a reasonable expectation of efficacy, highlighting the company's commitment to advancing animal health solutions.
• In November 2024, Ceva Santé Animale unveiled plans to construct a new vaccine manufacturing facility in Monor, Hungary, representing a significant investment to expand its global production capabilities. The company intends to utilize this new 7,000-square-meter plant to produce fermentation-based multicomponent inactivated vaccines, further strengthening its industrial footprint in the veterinary biologics sector. This strategic expansion was designed to address the growing global demand for preventive medicine and support poultry producers by ensuring a reliable supply of advanced vaccine technologies. The facility is expected to enhance the company's ability to combat major livestock diseases and emerging threats effectively.
• In November 2024, Boehringer Ingelheim launched a next-generation poultry vaccine in India designed to protect flocks against Marek's disease, a highly contagious viral infection. This new biological product features a serotype-1 construct and utilizes an innovative controlled attenuation process to deliver an optimal balance of safety and efficacy. The vaccine is recommended for in-ovo administration in embryonated eggs or subcutaneous injection in day-old chicks, providing early and long-lasting immunity. By introducing this advanced solution, the company aimed to support Indian poultry farmers in reducing disease outbreaks, improving flock health, and enhancing overall productivity in the region.
• In April 2024, Merck Animal Health entered into a strategic collaboration agreement with Cambridge Technologies to become the exclusive sales and marketing agent for the latter's autogenous poultry vaccines in the United States. Through this partnership, the company combined its extensive commercial reach with the partner's specialized expertise in molecular diagnostics and custom vaccine manufacturing. The collaboration was established to provide veterinarians and producers with tailored biological solutions capable of addressing specific and emerging disease challenges in flocks. This initiative underscored the company's dedication to delivering value through innovative, flock-specific disease management tools for the poultry industry.

Key Market Players

• Boehringer Ingelheim GmbH
• Zoetis Inc
• Elanco LLC
• Intervet Inc
• Hester Biosciences Ltd
• Vaxxinova GmbH
• Venky's India Ltd
• Laboratorios Calier SA
• KM Biologics Co Ltd
• Phibro Animal Health Corporation

By Application	By Product	By Disease Type	By Region
Broiler Layer Breeder	Attenuated Live Vaccines Inactivated Vaccines Subunit Vaccines DNA Vaccines Recombinant Vaccines	Infectious Bronchitis Infectious Bursal Diseases Infectious Laryngotracheitis Egg Drop Syndrome Adenovirus Duck Viral Enteritis Inclusion Body Hepatitis Salmonella Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Poultry Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Poultry Vaccines Market, By Application:

• Broiler
• Layer
• Breeder

• Poultry Vaccines Market, By Product:

• Attenuated Live Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• DNA Vaccines
• Recombinant Vaccines

• Poultry Vaccines Market, By Disease Type:

• Infectious Bronchitis
• Infectious Bursal Diseases
• Infectious Laryngotracheitis
• Egg Drop Syndrome
• Adenovirus
• Duck Viral Enteritis
• Inclusion Body Hepatitis
• Salmonella
• Others

• Poultry Vaccines Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE